Quotient Limited

Quotient Limited

QTNT

QTNTQuotient Limited US flag

NASDAQ Global Market

0.38

USD

- -

- -

CIK

0001596946

ISIN

JE00BLG2ZQ72

CUSIP

G73268107

Return %

Stock

S&P500

1Y

-99.33

26.53

3Y

-99.87

76.60

5Y

-99.73

80.11

Use logarithmic scale

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Company Description

CEO: Franz Walt
Full Time Employees: 450
Sector: Healthcare
Industry: Medical - Devices
Address: Jtc House, 28 Esplanade Switzerland 1262
IPO Date: Apr 16, 2014
CIK: 0001596946
Website: quotientbd.com
Similar Companies: Allmed Solutions Ltd (ALMD.TA)
PAVmed Inc. (PAVMW)
Median Technologies S.A. (ALMDT.PA)
Eurobio Scientific S.A. (ALERS.PA)
Guangdong Transtek Medical Electronics Co., Ltd (300562.SZ)
Belluscura plc (BELL.L)
Business: Quotient Limited is a commercial-stage diagnostics company specializing in transfusion diagnostics, with a product portfolio focused on blood grouping and serological disease screening. The company develops, manufactures, and markets innovative diagnostic tests and platforms, including its flagship MosaiQ platform, which provides multiplexing and multimodal capabilities for blood typing and disease screening. Quotient supplies conventional reagent products and whole blood controls used for quality assurance testing, selling directly to donor testing laboratories, hospitals, and independent patient testing laboratories primarily in Europe and the United States. It also provides products to original equipment manufacturers (OEMs) such as Ortho-Clinical Diagnostics, Bio-Rad Laboratories, and Grifols. The company operates globally with a strong presence in established transfusion diagnostics markets. Founded in 1996 and headquartered in Newtown, Pennsylvania, Quotient Limited has recently enhanced its technological offerings and market reach through strategic partnerships and financing initiatives. Notably, in 2025, it formed a multiyear strategic partnership with Intrepid Labs to integrate artificial intelligence into its early drug formulation and translational pharmaceutics platform, accelerating drug development processes. The company also expanded its service capabilities by recapitalizing with private equity firm Permira to broaden its formulation development and manufacturing capacities. Additionally, Quotient has signed distribution agreements in Southeast Asia, including partnerships with FAS Diagnostic Group and Transmedic, to extend the reach of its Alba by Quotient® and MosaiQ™ diagnostic solutions. These initiatives support Quotient's mission to reduce healthcare costs and improve patient care through innovation in transfusion diagnostics and early clinical drug development services. Quotient's core products and services include automated blood grouping and donor disease screening tests, multiplexed diagnostic platforms, reagent products for OEMs, formulation development, GMP manufacturing, early clinical testing services, and translational pharmaceutics solutions. The company continues to invest in advancing its MosaiQ platform preparing for commercial launch while expanding its global market footprint and strategic collaborations in AI-driven drug development and clinical testing services, ensuring growth and innovation in both the diagnostics and drug development segments. The company’s recent operational adjustments include voluntary delisting from Nasdaq to optimize liquidity and improve strategic financial positioning. This comprehensive product and service offering underlines Quotient's commitment to leading innovations in transfusion and pharmaceutical development diagnostics while executing a global expansion strategy.

Company News